BillionToOne, Inc. (BLLN) Earnings Call Transcript
December 9, 2025
Earnings Call Speaker Segments
Hello, everyone, and thanks for being here on today's call. With me from BillionToOne are Oguzhan Atey, our Co-founder and Chief Executive Officer, and Ross Taylor, our Chief Financial Officer. Earlier today, the company posted its financial results for the third quarter, which concluded on September 30th, 2025. You can find a copy of the press release on our website. Before we get started, please note that we may make forward-looking statements on this call as defined under federal securities laws. These statements regarding future events might cover our financial outlook and performance, market size, products and services, reimbursement coverage, future clinical performance, and other topics; be aware that they represent our current best judgment, and actual results could differ materially from what is expressed or implied in any forward-looking statement. Risk factors that could cause our results to differ are described in our filings with the SEC, including our previously filed registration statement on Form S-1, our quarterly report on Form 10-Q that will be filed after this call, and the current report on Form 8-K filed today. Any forward-looking statement shared on this call is made as of today, December 9th, 2025. Should this call be replayed or reviewed after today, the information provided may no longer be current or accurate. BillionToOne disclaims any obligation to publicly update any forward-looking statements, whether due to new information, future events, or otherwise, except as required by law. With that, I'll hand the call over to Oguzhan.
Thanks, David. Good afternoon, everybody. I appreciate you all joining us for our Q3 earnings call. This is our debut earnings call since becoming a public company, and we're eager to keep the conversation going with investors as the business expands in the coming years. Back in November, we wrapped up a successful IPO on NASDAQ, bringing in $314 million in gross proceeds for the company. I want to kick off this call by expressing gratitude to our committed and diligent team members, as well as our shareholders, since all of them helped make this major milestone achievable. A fresh chapter for BillionToOne is only getting started, and I'm thrilled about what lies ahead for us as a public company. Here at BillionToOne, we have four pillars of differentiation that we think set us apart as a different kind of molecular diagnostics company. All of our work begins with a groundbreaking single-molecule next-generation sequencing platform. This is made possible through our patented QCT, Quantitative Counting Template Technology, which delivers sensitivity and precision at the single-molecule level. Using this technology, we've created distinctive category-defining products in both prenatal and oncology. In prenatal, we're reshaping the meaning of non-invasive prenatal testing through our UnityToOne products by delivering a test that's more efficient and more sensitive, helping mothers learn about the health status of their developing babies. In oncology, we provide Northstar Select to assist with guiding therapy selection across multiple indications, plus Northstar Response, which assists physicians in tracking how a patient responds to therapies. Our prenatal and oncology offerings alike are highly differentiated and directly influence critical decision-making for patients. Our distinctive technology and product portfolio have driven exponential growth rates, even as we hit $334 million in annualized revenue run rate, or ARR, during the third quarter. That being said, we think we're only scratching the surface of what's achievable. Through our SMNGS technology, we think we're uniquely positioned to go after more than $100 billion in U.S. market opportunity over time. Importantly, possessing a unique technology and differentiated products enabled us to reach a superior gross margin profile, hitting 70% in Q3 2025, even with subscaled ASVs and utilizing only about one-fourth of our current lab capacity; we believe there's significant opportunity ahead for further ASV growth and COGS per test reductions, in both our prenatal and oncology product lines. Last but not least, I'm perhaps most proud of our capital and operational efficiency, which have enabled us to reach emerging profitability while growing at +100 %, an unprecedented feat in molecular diagnostics. As I've shared with the private and public investment community over the last five or more years and throughout the IPO roadshow, our long-term goal is to build a category-defining generational company and become a member of the S&P 500. Our Q3 performance and achievements allowed us to keep making important strides towards this goal, and the results are simply stunning. Our game-changing SMNGS platform and offerings keep getting endorsement through both partnerships and publications—two of those focused on prenatal, a head-to-head trial involving Northstar Select, plus an exclusive deal with Johnson & Johnson—and I'll walk through each of those on the slides coming up. On the revenue and test volume side, we're still expanding at a fast clip, having posted 51% growth in tests and 117% growth in revenue compared with a year earlier during Q3. Gross margins came in at an outstanding 70%, which is 17 percentage points better than a year ago, driven by strong outperformance in ASVs along with ongoing declines in cost per test. We managed to deliver that expansion while reaching emerging GAAP profitability, with an 11.5% positive GAAP operating margin, and we brought every year-to-date GAAP profitability metric into positive territory. Ross and I will give you a closer look at the quarter, though before that I'd like to update you on several exciting publications and business developments. Lately we've landed notable prenatal and oncology papers in peer-reviewed journals. Most notably, the biggest Cystic Fibrosis study conducted in a prenatal setting, which appeared in the Journal of Cystic Fibrosis, showed 100% sensitivity for UnityToOne when identifying pregnancies at high risk for Cystic Fibrosis. Crucially, 95% of those cases qualified for Cystic Fibrosis modulator therapies, which underscores the clinical utility of our approach. A separate UnityToOne paper in pregnancy confirmed the clinical utility of fetal antigen cell-free DNA testing and points to the benefit of bringing precision to pregnancies at risk for hemolytic disease of fetus and newborn, or HDFN, something UnityToOne delivers. Lastly, we completed an exclusive agreement that makes us the official companion diagnostic partner to Johnson & Johnson for hemolytic disease of fetus and newborn. That puts our UnityToOne fetal antigen test for treatment of HDFN as the first CDx of its kind within the NIPT space, and every milestone so far has been met successfully. Moving to oncology, Northstar Select showed superior sensitivity in a prospective head-to-head validation study that ran in the Journal of Liquid Biopsy. For that study, we had clinicians nationwide use whatever liquid biopsy they already rely on for standard of care, but for the same patient, on the same day, within the same blood draw, send us an additional tube of blood too. We didn't dictate which test they ought to use, and we didn't establish inclusion/exclusion criteria. In the end, we published our results while the other liquid biopsy companies published theirs. What we show here is that in this head-to-head study, we picked up 51% more pathogenic SMVs and 109% more copy number variants relative to those comparators. These publications give further validation to how transformative UnityToOne and Northstar tests are, and with these differentiated products, we've been able to fuel rapid growth. That rapid growth looks even more striking as our organization scales. During Q3 2025, total test accession for the quarter rose 51% year-over-year, reaching 163,000 tests. Robust growth in test volume came from our commercial team widening the geographic footprint as we move into new markets, plus greater commercial density in markets where we already operate, alongside an expansion of in-network status with commercial payers. On top of that, we've observed acceleration even among larger health system adoptions, and that was among the factors behind our growth; in our view, the rival product launches for fetal risk assessment confirm the market need we spotted in this space over five years back. Because of the considerable technology differentiation, more than five years of peer-reviewed publications, and the substantial product advantages we hold, no effect on our business has appeared thus far, as reflected in the growth we delivered this quarter and through today. Another point worth noting is that this remarkable growth has come without us having put comparable levels of investment into EMR; even so, since a greater share of our growth is beginning to stem from broad health system adoptions throughout the United States, we chose to commit more resources here. Accordingly, the contract with Epic for Aura implementation has been signed. It could take nine months before it goes live, but once it does, we expect it to eliminate one of the largest obstacles to quicker UnityToOne adoption among health systems nationwide. Total revenue for Q3 2025 came to $83.5 million, up 117% from $38 million in Q3 2024.
This quarter's numbers came from strong growth in test volume, plus rising average selling prices—ASVs—across the entire product lineup, and I'll get into what's behind those drivers shortly. Standout results on every metric produced 25% sequential growth from Q2. ARR reached $334 million, which is roughly a $69 million sequential gain versus Q2 ARR, underscoring demand for our test and the broader momentum in our business. That outperformance came from fast growth in prenatal and oncology revenues alike; prenatal revenue in Q4 hit $74 million, up 101% year-over-year. Oncology is expanding at an even quicker pace than prenatal, generating $8.7 million of revenue in Q4, which is 664% growth relative to Q3 of last year. Revenue performance stemmed from rapid test volume gains in both select and response tests, together with better ASVs. Over the past two years, since we first launched our Northstar Select products, oncology has grown tremendously, and we keep expanding our oncology sales team as we grow; we see a large future opportunity for Northstar Select as coverage decisions broaden, particularly for Northstar Select Response, to support meaningful revenue opportunities in the years ahead. Our superior gross margin profile comes from both expanding ASVs and lower cost per test. Blended ASV overall was $501 in Q4, an impressive 44% year-over-year increase, with 10% sequential quarter-over-quarter growth. The main forces behind ASV growth have been expanded payer coverage in prenatal as we build our commercial contracting efforts to roughly 235 million contracted lives now. We also moved reimbursement in-house last year, and our team keeps making strides toward getting more of our tests paid. Lastly, more Medicaids have been loading and covering the UnityToOne carrier panel PLA code, which has added incremental ASV improvement. We keep broadening coverage for specific portions of our test as we drive ASV improvement over time. Beyond driving ASV growth, we've stayed committed to our operating philosophy of continuous improvements aimed at lowering the total cost per test. In Q3 2025, our blended cost per test fell by 10% to $151, mainly due to our cost initiatives and higher volumes pushing fixed cost per test down. This decrease happened even with an increasing shift toward a higher proportion of revenues coming from oncology, which, of course, as you know, carries higher COGS per test, plus higher stock-based compensation expense as we move toward being a public company. As BillionToOne's overall COGS has fallen and overall blended ASVs have risen, gross margins have expanded rapidly. Gross margins were 70% in Q3 versus 53% in Q3 of 2024, a remarkable 17 percentage point increase. Since our earliest days, we have been highly capital-efficient, prioritizing spend with purpose and focus on efficiency. As a public company going forward, our plan is to keep applying that same rigorous, disciplined method when it comes to investing and expanding, so that profitability keeps being driven; having said that, I'll now hand things over to Ross so he can walk through the financial results and give the 2025 guidance, after which I'll wrap up.
Thanks, Oguzhan. As Oguzhan mentioned, we brought in $83.5 million in total revenue for Q3 of 2025, up from $38.4 million in Q3 of 2024 — that's a 117% rise. On top of that, both our prenatal and oncology product lines posted solid revenue growth during the quarter. Prenatal revenues came to $74.8 million in Q3, an increase of just over 100%, and that figure is made up of $74.1 million from clinical testing plus about $800,000 from clinical trial support and other services. Oncology revenues rose 7.6 times to $8.7 million in Q3 of 2025 versus the same period last year, and they were up 76% sequentially from $4.9 million in Q2 of 2025. The main drivers behind our overall revenue growth were higher test volumes in both prenatal and oncology, along with rising prenatal and oncology ASPs. Our total revenues also included true-up revenue tied to greater cash collections on tests delivered in earlier periods. True-up revenue came to $3.7 million in Q3 of 2025 and $8.7 million for the nine months ending September 30th, 2025. By contrast, true-up revenue was $1.4 million in Q3 of 2024 and $10.2 million for the first nine months of 2024. If you set aside true-up revenue, total revenue growth in Q3 reached 116% versus the same period last year. Gross profit for Q3 of 2025 came in at $58.4 million, versus $20.2 million in Q3 of 2024, which works out to a gross margin of 70% in Q3 of 2025 and 53% in Q3 of 2024. The margin improvement came mainly from higher overall ASV and a lower overall cost per test. I'd point out that ASVs and cost per tests got better across every one of our product lines this quarter. Total operating expenses reached $48.8 million in Q3 of 2025, up 49% from $32.8 million in the comparable prior year quarter. Breaking that down, R&D expense was $13.0 million in Q3 of 2025 versus $9.6 million in the comparable prior year quarter, and SG&A expense was $35.8 million in Q3 of 2025 versus $23.3 million in the comparable prior year quarter. We're still scaling our operating expenses to back rapid growth with efficiency and discipline. Operating income was $9.6 million in Q3 of 2025, compared with an operating loss of $12.6 million in Q3 of 2024. Our Q3 operating profit margin was 11.5%. Q3 2025 marks the first quarter we've delivered positive GAAP operating income, and it came faster than we'd anticipated thanks to the strong gains in revenues and gross margins we saw during the quarter. We intend to run our business so that we keep producing positive GAAP operating income going forward. Net income available to common shareholders was $1.5 million, or $0.10 per diluted share, in Q3 of 2025, versus a net loss of $14.9 million, or $1.47 per diluted share, for the same period in 2024. For the third quarter of this year, the weighted average diluted shares outstanding applied when figuring net income per share came to 15.6 million shares. Operating cash flow, after subtracting capital expenditures and investments, totaled $7.9 million in Q3 of 2025, and $6.5 million across the first nine months of 2025. Net cash flow for those same periods, respectively, was $6.2 million and $3.7 million. After the upsized IPO and the exercise of the green shoe, diluted shares outstanding should land somewhere between $55 million and $56 million over the coming quarters for modeling purposes. Keep in mind that weighted average diluted shares will come in lower for Q4, since the IPO took place in early November. On the last point, our capitalization is strong and our balance sheet is very solid; we closed Q3 with roughly $195 million of cash and equivalents. After Q3 ended, we brought in about $314 million of gross proceeds, equal to $286.4 million of net proceeds, from our initial public offering. That very healthy balance sheet leaves us positioned for strong growth ahead, especially in light of our intention to keep running the business for profitability and positive cash flow. To wrap up, I'll give our full year guidance for 2025. For 2025, we anticipate total revenue between $293 million and $299 million, which works out to a remarkable 92% — 96% growth versus 2024. Included in that guidance is an expectation for Q4 revenue of $84 million-$90 million, amounting to growth of over 86%-100% versus Q4 of last year. We'd note that even though Q4 is historically a seasonally slower quarter for our business — because there are fewer accessioning days in most of the larger clinics, and health systems tend to prefer pushing their switches from one laboratory to another laboratory into January — our business momentum stayed strong in Q4. That leads us to anticipate modest sequential quarter-on-quarter growth from Q3 to Q4, even following an exceptionally strong Q3 in which every single metric beat our expectations. At the midpoint, the year-over-year growth we project for Q4 ranks as the second highest year-over-year percentage we expect to deliver since July of 2024, which underscores our continued momentum. On top of that, we expect positive GAAP operating income for Q4 as well as for the full year of 2025. I'll now hand the call back to Oguzhan to conclude.
To wrap up, BillionToOne has achieved significant strides during this year, with exceptional results in the third quarter of 2025. Even so, we feel that what lies ahead is only the start. We're reshaping medicine molecule by molecule, patient by patient, aiming to create a company that defines its category and to be the first among our peers to join the S&P 500. To recap, during this quarter, fresh publications have come out backing the superiority of our test and technology. Our Q3 beat expectations across every key metric, which made it the strongest quarter compared to last year, and we're still making investments in expanding our sales force as well as in areas like EMR. This leads us to guide toward 90% year-over-year growth for both Q4 and the entirety of 2025. I'm extremely enthusiastic about what's next for BillionToOne, and I have full confidence in our capacity to favorably alter the path of millions of patients' lives. At this point, I'll hand the call over to the operator for the Q&A. Operator.
Hey there, everyone. Congratulations on the IPO and on your first quarter since going public. I appreciate you fielding the questions. To kick things off, it's great to see that positive GAAP net income figure. I caught your remarks about anticipating that it stays positive in Q4. I'm wondering whether that's also what you intend for 2026? Of course, I understand you're stepping up certain investments in the business, likely in oncology too. So what's the right way for us to frame GAAP net income for 2026, or perhaps adjusted as well?
Mark, thank you, and thanks for those kind remarks. We'll be saving the precise guidance for 2026 for the JPMorgan Healthcare Conference, but as I believe we've said before, our objective is to keep expanding this company profitably. That's a goal I expect we'll keep upholding in the years ahead.
All right, that's excellent. Then perhaps regarding oncology — I realize it's still early, but I'm interested. From what I understand, you've had your initial test get reimbursement through Medicare. The second one as well, I believe. Oguzhan, I'd like to know how you're viewing the timeline on that front. And could you also help us understand how big an investment you intend to make during 2026? No need for specific figures — just your thinking at a strategic level.
Yes, thanks, Mark. We've put substantial money into clinical trials already for our Northstar Select Response coverage. Our view is that the trials required to secure coverage are now finished; during 2026 we'll add further studies on top of that, though we expect that the initial Medicare reimbursement for Northstar Select Response — depending on how the MolDX conversations and exchanges unfold — will arrive prior to the close of 2026.
That works well. I'll rejoin the queue. Appreciate it.
Thanks, Mark.
Hello, Oguzhan. Hello, Ross. Good afternoon, and thank you for taking my question. Since this marks the first occasion you're issuing guidance as a publicly traded company, could you perhaps walk through the general approach you follow when putting guidance out there? And I suppose tied to that, what's the broader thinking around building in caution, or those margin-of-error bands, for the forecast period?
Thanks, Andrew. For roughly the past 2 to 3 years, we've essentially been running ourselves much like a public entity. You might recall that we even disclosed certain projections during the JPMorgan conference earlier in 2025, covering both 2025 and 2026. Based on the figures we've managed to deliver, those projections reflected a cautious stance. Broadly speaking, our business tends to be quite repeatable and predictable, yet there are also numerous tailwinds we choose not to factor into our models, particularly when it comes to ASV growth. Consequently, many of our test volume figures remain cautious yet predictable. However, ASV gains typically don't get baked into the guidance to the same degree. Thus, many tailwinds we observe regarding expanded coverage and expanded contracting, driven by more of our tests being reimbursed, lead to results exceeding our projections. I'd point out as well that we're nearly at the conclusion of this year, so the guidance we're presenting, at minimum for Q4 and 2025, is in fact fairly precise.
That's perfect.
Yeah, I might just add.
My apologies, Ross.
Yes, let me just say this — in certain respects, what we've released regarding Q4 guidance is kind of comparable, or close, to how we handled the Q3 flash figures in the S-1. Our aim was to sort of frame the range of what we expect; therefore, I believe the Q4 guidance range we've issued is fairly sensible. All right.
I appreciate that additional detail; regarding what we're putting into the EMR, I understand it will require a number of quarters to implement across the board; however, at a conceptual level, how should we be approaching the chance here and the effect it could deliver for your company? Whenever you talk with clients, what portion of those discussions is prompting this choice, and how ought we to consider the outcome and the benefit you may ultimately capture? Thank you for asking that.
Yes, thanks, Andrew. This is something that I believe a lot of the analysts have also found through their own separate research. This is something we have not put as much money into relative to other businesses since it can add substantial expense to carry out certain of these tasks. It may run into millions of dollars, yet I believe what we are coming to see and acknowledge is that as we bring on a growing number of health systems, this turns out to be truly the sole barrier to winning over very high volume health system accounts to our side, so we think this will basically speed up our uptake among these big health systems quite dramatically once it goes live. It is likewise a thing where we have likely been the lone prominent organization that has not pursued it, so I think it is quite striking that we could expand in the absence of it, yet honestly, this unlocks close to roughly half of this prenatal market that previously was far harder for us to break into since they truly desire those EMR integrations in order to place orders for this. As you are aware, particularly within the prenatal context, simplicity of use matters greatly. Indeed, that is among the value propositions of Unity Fetal Risk Screen; it provides a far simpler means to screen pregnancies for an extremely broad array of conditions; yet naturally, lacking EMR was fundamentally at odds with that simplicity of use; so through making this investment, I believe we will reach parity with competitors, and that should genuinely propel our ongoing expansion at the rates we have witnessed previously.
All right. I appreciate that question.
Hello. Thank you for fielding this, and I share the sentiment. Congratulations on the IPO and on the strong debut; so your annual clinical spending sits at roughly $50 million, while a number of your rivals are putting out 10x that amount. Do you believe you're allocating enough? And what's your thinking around study design in oncology? We're grateful for the data you shared regarding 51% gains in indels, SMVs, and a copy number variant, and so on, up 100%. Yet at the end of the day, what your test does is uncover more actionable mutations that place patients on the correct therapy. Do you think you might be conducting larger studies, ones that perhaps look at OS and disease-free survival? I'd contend that you, much like your competitors, are building markets in this space too. So I realize that was a lengthy question, but I have one thing to follow up with.
Thank you. Thanks, Dave, for asking that. So I believe we understand that putting money into clinical studies matters. Yet as we put money into clinical studies, we're also genuinely attempting to grasp what the question we're answering happens to be and whether it will add something to what physicians are looking for. So regarding therapy selection, naturally, I'd say I'm with you that we're uncovering — and we've demonstrated, I'd argue, quite definitively — that we're uncovering additional mutations. Does that translate into improved outcomes, clinical outcomes, for the patients? In our conversations, at least with the physicians, that isn't a question or a worry on their end; so those studies could be run by us, yet I don't believe it would really shift the adoption curve we're witnessing in this highly established therapy selection space. Conversely, though, as we move into newer spaces such as response monitoring and MRD, I'm of the view that bigger studies and greater investment are definitely warranted, since those are spaces where physicians might be somewhat less at ease, correct? When they essentially see an EGFR mutation or a KRAS mutation that we pick up, I think the physicians, I think, inherently grasp and recognize that this will result in a better outcome for the patient. But that isn't, I think, as plainly shown in the response and MRD spaces — not only by us, but broadly across all the various diagnostics companies — that particularly beyond the adjuvant setting, if you catch progression early, if you're conducting surveillance with MRD, does that produce better clinical outcomes? And in those spaces, I think it's crucial to keep investing. But we will always be extremely deliberate about which studies we run. So our investments will continue. Our investments will grow as we move into, particularly, MRD. Yet I'd add that plenty of spending occurs in this space which may fail to make any real difference; therefore our focus is on trials that genuinely address the inquiries oncologists bring. That point, in my view, truly matters and varies by area. When it comes to therapy selection, I doubt it's OS, though for response monitoring and MRD, that could well be the case.
Thanks a lot. And staying on Oncology, when it comes to test volumes per patient, how do you view the split between monitoring and therapy selection? Could you talk about whether a physician might ever rely on only one of your tests while turning to a competitor for the other? I wouldn't imagine that happens very often, but can you describe the situations where it does? I'm just trying to understand that mix going forward and what kinds of variables might shift it.
That's a great question. When it comes to Response and monitoring tests, we observe approximately a 2-to-1 ratio of Response tests to Select tests. So 95% of our providers, as we mentioned during the roadshow, in fact use Select and Response together. So a physician using only Select or only Response is quite uncommon. What we observe once they've used Select and Response together is that certain physicians will actually repeat both Select and Response, while others may run more Response tests until they observe progression, and then they use another Select test. On a Per-Patient basis, we are in fact seeing definitely more than 1 Select usage. We observe a 2-to-1 ratio of Response to Select, though that's on more of a blended basis simply because different physicians use it differently. A few of them only alongside Select. A few of them use Response for follow-up, and then they observe progression, and then they use Select.
Thank you very much.
Thank you, Dave.
I appreciate you fielding my questions, and congratulations on the IPO. For my first one, I'm interested in what's happening with sales force growth. What number of reps should we expect you to bring on during Q4, and how do you anticipate growing the sales force in 2026, for both prenatal and Oncology?
Thanks, Casey. Our approach to expanding the sales team has stayed quite consistent. On the prenatal side, we add eight to 10 net reps each quarter, while Oncology gets roughly four to six or seven per quarter. Naturally, this shifts around from one quarter to the next, yet our approach to bringing these reps on board has stayed steady. Thanks to that, we can expand while keeping service levels outstanding. Our turnaround time stays strong. Every support function is scaling at comparable rates too. On top of that, it genuinely lets us bring in only the finest people — truly the top 1% of applicants. So, when I look at our sales efficiency figures, it could seem wise to push this expansion much faster, given how efficient and effective our sales teams are. Still, our view is that approaching this in a systematic, intentional manner has worked to our advantage up to this point. So going forward, our plan is to stick with that same approach.
Understood, that's useful. Now for my next question, perhaps. You brought up improved traction with Medicaid regarding the Unity Carrier panel — or rather, the Unity Carrier panel code. So, what I'd like to know is, how significant was that to ASP growth during the quarter, and what should we expect from that contribution in Q4 and looking further ahead? Thank you.
Essentially, it's hard to forecast a single change translating into particular dollar figures for ASP; however, to help you understand just how meaningful this could be, when comparing the carrier code, standard carrier panels, against our PLA code, there's nearly a 2x gap in terms of where the ASPs sit. So viewed that way, essentially, even one Medicaid program adding our PLA code to its coverage policy could prove substantial. And that's not only substantial regarding the state Medicaid lives — it also enables us afterward to manage Medicaid within that state and add our PLA code into those contracts too. So the complete effect does require time before it's reflected in our ASPs, yet I believe it genuinely establishes a distinct long-term ASP target for us as we essentially secure more Medicaid coverage for our PLA code.
All right, that's useful. Appreciate it, everyone. We're excited to see you at our event taking place next month.
Thanks, Casey.
Hi there, thank you. Good afternoon. Ross, that 70% gross margin for the quarter was a pretty impressive result. Should we be treating that as the new standard as we head out of this year and into 2026? And could you also discuss which other areas still offer room for bringing down the COGS per test across the coming one to two years?
Sure. I'd say we aren't really in a position yet to discuss 2026 and gross margins, Brandon, though expecting that we stay somewhere in the high 60s% seems like a fairly sensible assumption for at least the upcoming few quarters. As you're probably aware, there's a negative mix shift we're dealing with, since the oncology products carry lower gross margin yet are expanding considerably quicker. That produces a sort of negative mix shift relative to prenatal. So Q3 gross margins were really good, but versus what we've discussed lately, I don't believe our gross margin expectations have truly shifted.
Yes, and just to tack on a small point there, Brandon — I believe the outcome hinges heavily on how quickly our ASPs climb, how quickly our COGS come down, and how those compare against the shift in mix. On the prenatal side, our ASPs are rising fairly well, in my view. Our COGS keep falling because we're drawing on more of our lab capacity, and that holds especially true over in Oncology. So when you examine each of these products individually, ASPs are going up while COGS go down. Over time, the gross margin on every product is widening; however, since our oncology revenue is expanding at a quicker pace, you basically wind up with those forces pushing against each other. So the answer really comes down to just how rapidly each product's gross margin keeps widening relative to how fast each of those products grows. That said, as Ross mentioned, we anticipate holding at essentially high 60s%, low 70s% while we keep growing.
All right, that's clear. Then, Ross, one point I'd like clarified: does the fourth quarter revenue outlook include any true-up revenue? And then, when we consider 2026, please discuss the key data readouts or clinical or reimbursement milestones that ought to be on our radar for next year. Thank you.
Certainly. Regarding your question on revenue, Brandon, across the first nine months of this year, true-up revenues accounted for between 3% and 5% of revenues. Our expectation, I believe, would be for Q4 to fall somewhere within that same range as well. So a modest true-up amount, which I think aligns with what has been observed this year.
Regarding what the readout shows, our clinical studies are still ongoing, particularly for Northstar Select Response. To help secure reimbursement for Northstar Select Response, the most significant milestone, I believe, would be landing our initial Medicare/MolDX coverage for Northstar Select Response. That stands as a major initiative and a key objective for 2026. And since we have that ratio of two response to one select, any rise in response ASPs would matter a great deal for our oncology gross margins and for our oncology revenues alike.
Great. Thank you.
Hey, thank you. One thing people keep asking us since the IPO is about MRD — specifically, what timelines should we expect for data, which indications will you go after first, and what makes you confident you can win in that space. Could you speak to that in the context of the pipeline?
Sure. Our view on MRD is that it will divide into 2 categories, particularly as time goes on and particularly once we move beyond colorectal cancer into additional cancer types: tumor-informed and tumor-naive. As you're probably noticing more and more, the tumor-informed space is going to become extremely crowded. Basically, hitting clinical LODs of 1 to 10 PPM will be achievable through a wide range of approaches; over time, these ultra-sensitive assays will genuinely be battling one another, backed by solid clinical data, on the tumor-informed side too. What we're aiming at is tumor-naive MRD. In that setting, our technology actually addresses the core issue that pushes all these other companies toward tumor-informed MRD. Right? Why would anybody build a tumor-informed MRD? It certainly isn't the least expensive option, and it isn't what physicians are asking for. It's harder to use. The reason they go tumor-informed is that if you already know where to look within cell-free DNA, you can reach those ultra-sensitive thresholds. Our technology — our SMNGS, QCT, Quantitative Counting Template Technology — tackles precisely this noise issue. Right? What we're essentially doing is eliminating the noise that those companies attempt to eliminate by adopting a tumor-informed MRD approach. So from that angle, we think we can reach ultra-sensitive sensitivity levels with a tumor-naive test at a level no other company has managed to come anywhere close to so far. So on the technology front, that's why we think we have the right to win in tumor-naive MRD, and why we can address a problem that truly defeats a lot of different methodologies. It really comes down to a technology question, and our technology is very uniquely suited to that noise problem — the very thing that people solve by going with tumor-informed MRD. As for our data readout and strategy there, it will be a pan-cancer assay, much like the response monitoring approach we've adopted. Naturally, though, we'll want to launch with data. We anticipate launching toward the end of 2026, essentially around the same period when we expect to secure coverage for our response test. From a growth standpoint, we've always held the philosophy of having just one test lacking broad coverage and high gross margins. After Medicare begins covering our response monitoring, our plan is to introduce MRD for a pan-cancer indication, though we obviously recognize that reimbursement for our MRD will not be in place, at minimum during the initial 1 year of commercialization.
All right, that's quite useful. Then regarding UnityToOne, I believe you mentioned that particular segments might gain broader reimbursement. My assumption is that applies to carrier screening. Also, has anything shifted when it comes to competition? Clearly, a rival of yours rolled out the Fetal Focus assay. Are you noticing any differences in today's market?
Sitting here on December 9, I observe zero effect on our company from rivals' product introductions; in certain respects, it's almost as though nothing occurred. From that angle, we keep expanding just as anticipated. I'd say that's a positive. In certain respects, it might drive updates to guidelines, greater visibility, yet we additionally hold a considerable, I'd argue, advantage in how we tackle this, in how simple our solution is to use, in the manner we're going after this specific market. Thus up to now, zero effect, as reflected in the Q3 figures and I believe as built into our Q4 guidance.
Okay. Thanks.
And thanks for every question. This was the first time we reported earnings since becoming a public company. We're really enthusiastic about what lies ahead for us and about the ways we can keep expanding, keep transforming the standard of care, and keep building a molecular diagnostics business of a different kind — one that pairs hypergrowth with profitability. We think we've demonstrated that this can be done, and we're on a 20-mile march to prove that a company in this space can even make it into the S&P 500. So thanks for all the questions and for listening to us today, and we hope to see you on future earnings calls.
Thanks everyone for being part of the call today. That brings the program to a close. You're welcome to hang up now. Have a wonderful day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete BillionToOne, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to BillionToOne, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.